Archives of Obesity and Metabolism (비만대사연구학술지)

The Study of Obesity and Metabolic Syndrome, KAFM (대한가정의학회 비만대사증후군연구회)
권호 표지
DOI QR코드

DOI QR Code

Management of Chronic Kidney Disease in Obesity Patients

비만환자의 만성콩팥병 관리

  • Han, Kunhee (Department of Family Medicine, Seoul Medical Center)
  • Received : 2022.10.18
  • Accepted : 2022.12.14
  • Published : 2022.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Obesity is an increasing public health and medical issue worldwide. It has been associated with several comorbidities, including diabetes, cardiovascular disease, stroke, and cancer. Chronic kidney disease (CKD) is another important comorbidity of obesity. Other major causes of CKD include hypertension and diabetes. However, the association between obesity and CKD is often overlooked. Among patients with CKD, patients with obesity were more vulnerable to have rapid kidney function decline than that of those with normal weight. Additionally, CKD is more prevalent among patients with obesity. These aggravations are induced through multiple mechanisms, specifically metabolic impairment of obesity and mechanical burden because of increasing intraabdominal renal pressure. Furthermore, the inflammation and lipotoxicity, caused by obesity, are critical in the CKD aggravation in patients with obesity. To prevent this, all adult patients with obesity are tested for CKD. The workup includes the estimated glomerular filtration rate and regular follow-up. Step-wise management is required for patients with obesity with CKD. Prompt reduction and management of obesity effectively delay CKD progression among patients with obesity and CKD. Therefore, weight loss is a core management for patients with obesity and CKD. Based on several studies, this article focused on the association between CKD and obesity, as well as the diagnosis and weight management of patients with obesity and CKD.

Keywords

References

  1. Upadhyay J, Farr O, Perakakis N, Ghaly W, Mantzoros C. Obesity as a disease. Med Clin North Am 2018;102:13-33. https://doi.org/10.1016/j.mcna.2017.08.004
  2. Martin-Rodriguez E, Guillen-Grima F, Marti A, Brugos-Larumbe A. Comorbidity associated with obesity in a large population: the APNA study. Obes Res Clin Pract 2015;9:435-447. https://doi.org/10.1016/j.orcp.2015.04.003
  3. Pi-Sunyer X. The medical risks of obesity. Postgrad Med 2009;121:21-33. https://doi.org/10.3810/pgm.2009.11.2074
  4. Hsiao LL. Raising awareness, screening and prevention of chronic kidney disease: it takes more than a village. Nephrology (Carlton) 2018;23 Suppl 4:107-111. https://doi.org/10.1111/nep.13459
  5. Chen T, Harris DC. Challenges of chronic kidney disease prevention. Med J Aust 2015;203:209-210. https://doi.org/10.5694/mja15.00241
  6. Foster MC, Hwang SJ, Larson MG, et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 2008;52:39-48. https://doi.org/10.1053/j.ajkd.2008.03.003
  7. Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. Am J Kidney Dis 2005;46:587-594. https://doi.org/10.1053/j.ajkd.2005.06.007
  8. Gelber RP, Kurth T, Kausz AT, et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 2005;46:871-880. https://doi.org/10.1053/j.ajkd.2005.08.015
  9. Lu JL, Molnar MZ, Naseer A, Mikkelsen MK, Kalantar-Zadeh K, Kovesdy CP. Association of age and BMI with kidney function and mortality: a cohort study. Lancet Diabetes Endocrinol 2015;3:704-714. https://doi.org/10.1016/S2213-8587(15)00128-X
  10. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006;144:21-28. https://doi.org/10.7326/0003-4819-144-1-200601030-00006
  11. Vivante A, Golan E, Tzur D, et al. Body mass index in 1.2 million adolescents and risk for end-stage renal disease. Arch Intern Med 2012;172:1644-1650. https://doi.org/10.1001/2013.jamainternmed.85
  12. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004;65:1870-1876. https://doi.org/10.1111/j.1523-1755.2004.00582.x
  13. Pinto-Sietsma SJ, Navis G, Janssen WM, de Zeeuw D, Gans RO, de Jong PE. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis 2003;41:733-741. https://doi.org/10.1016/S0272-6386(03)00020-9
  14. Kramer H, Gutierrez OM, Judd SE, et al. Waist circumference, body mass index, and ESRD in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis 2016;67:62-69. https://doi.org/10.1053/j.ajkd.2015.05.023
  15. Evangelista LS, Cho WK, Kim Y. Obesity and chronic kidney disease: a population-based study among South Koreans. PLoS One 2018;13:e0193559. https://doi.org/10.1371/journal.pone.0193559
  16. Scales CD Jr, Smith AC, Hanley JM, Saigal CS; Urologic Diseases in America Project. Prevalence of kidney stones in the United States. Eur Urol 2012;62:160-165. https://doi.org/10.1016/j.eururo.2012.03.052
  17. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005;293:455-462. https://doi.org/10.1001/jama.293.4.455
  18. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 2014;384:755-765. https://doi.org/10.1016/S0140-6736(14)60892-8
  19. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-578. https://doi.org/10.1016/S0140-6736(08)60269-X
  20. Nam GE, Cho KH, Han K, et al. Obesity, abdominal obesity and subsequent risk of kidney cancer: a cohort study of 23.3 million East Asians. Br J Cancer 2019;121:271-277. https://doi.org/10.1038/s41416-019-0500-z
  21. Bluher M. The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. Curr Opin Lipidol 2010;21:38-43. https://doi.org/10.1097/MOL.0b013e3283346ccc
  22. Kopple JD, Feroze U. The effect of obesity on chronic kidney disease. J Ren Nutr 2011;21:66-71. https://doi.org/10.1053/j.jrn.2010.10.009
  23. Hall JE, Henegar JR, Dwyer TM, et al. Is obesity a major cause of chronic kidney disease? Adv Ren Replace Ther 2004;11:41-54. https://doi.org/10.1053/j.arrt.2003.10.007
  24. Kopple JD. Obesity and chronic kidney disease. J Ren Nutr 2010;20(5 Suppl):S29-S30. https://doi.org/10.1053/j.jrn.2010.05.008
  25. Levin A, Stevens PE, Bilous RW, et al.; Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150. https://doi.org/10.1038/kisup.2012.73
  26. Stevens LA, Manzi J, Levey AS, et al. Impact of creatinine calibration on performance of GFR estimating equations in a pooled individual patient database. Am J Kidney Dis 2007;50:21-35. https://doi.org/10.1053/j.ajkd.2007.04.004
  27. Matsushita K, Selvin E, Bash LD, Astor BC, Coresh J. Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2010;55:648-659. https://doi.org/10.1053/j.ajkd.2009.12.016
  28. Kilbride HS, Stevens PE, Eaglestone G, et al. Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKDEPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderly. Am J Kidney Dis 2013;61:57-66. https://doi.org/10.1053/j.ajkd.2012.06.016
  29. Sriperumbuduri S, Dent R, Malcolm J, et al. Accurate GFR in obesity-protocol for a systematic review. Syst Rev 2019;8:147. https://doi.org/10.1186/s13643-019-1052-2
  30. Wuerzner G, Bochud M, Giusti V, Burnier M. Measurement of glomerular filtration rate in obese patients: pitfalls and potential consequences on drug therapy. Obes Facts 2011;4:238-243. https://doi.org/10.1159/000329547
  31. Lemoine S, Panaye M, Pelletier C, et al. Cystatin C-creatinine based glomerular filtration rate equation in obese chronic kidney disease patients: impact of deindexation and gender. Am J Nephrol 2016;44:63-70. https://doi.org/10.1159/000447365
  32. Miles Maliska C 3rd, Jennings W, Mallios A. When arteriovenous fistulas are too deep: options in obese individuals. J Am Coll Surg 2015;221:1067-1072. https://doi.org/10.1016/j.jamcollsurg.2015.09.004
  33. Plumb TJ, Adelson AB, Groggel GC, Johanning JM, Lynch TG, Lund B. Obesity and hemodialysis vascular access failure. Am J Kidney Dis 2007;50:450-454. https://doi.org/10.1053/j.ajkd.2007.06.010
  34. Obi Y, Streja E, Mehrotra R, et al. Impact of obesity on modality longevity, residual kidney function, peritonitis, and survival among incident peritoneal dialysis patients. Am J Kidney Dis 2018;71:802-813. https://doi.org/10.1053/j.ajkd.2017.09.010
  35. McDonald SP, Collins JF, Johnson DW. Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations. J Am Soc Nephrol 2003;14:2894-2901. https://doi.org/10.1097/01.ASN.0000091587.55159.5F
  36. Lafranca JA, IJermans JN, Betjes MG, Dor FJ. Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis. BMC Med 2015;13:111. Erratum in: BMC Med 2015;13:141. https://doi.org/10.1186/s12916-015-0340-5
  37. Sood A, Hakim DN, Hakim NS. Consequences of recipient obesity on postoperative outcomes in a renal transplant: a systematic review and meta-analysis. Exp Clin Transplant 2016;14:121-128.
  38. Cannon RM, Jones CM, Hughes MG, Eng M, Marvin MR. The impact of recipient obesity on outcomes after renal transplantation. Ann Surg 2013;257:978-984. https://doi.org/10.1097/SLA.0b013e318275a6cb
  39. Bolignano D, Zoccali C. Effects of weight loss on renal function in obese CKD patients: a systematic review. Nephrol Dial Transplant 2013;28 Suppl 4:iv82-iv98. https://doi.org/10.1093/ndt/gft302
  40. Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145-154. Erratum in: N Engl J Med 2014;370:1866. https://doi.org/10.1056/NEJMoa1212914
  41. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med 2017;376:254-266. https://doi.org/10.1056/NEJMra1514009
  42. Pi-Sunyer X. The look AHEAD trial: a review and discussion of its outcomes. Curr Nutr Rep 2014;3:387-391. https://doi.org/10.1007/s13668-014-0099-x
  43. Look AHEAD Research Group, Gregg EW, Jakicic JM, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2016;4:913-921. https://doi.org/10.1016/S2213-8587(16)30162-0
  44. Morales E, Valero MA, Leon M, Hernandez E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003;41:319-327. https://doi.org/10.1053/ajkd.2003.50039
  45. Tirosh A, Golan R, Harman-Boehm I, et al. Renal function following three distinct weight loss dietary strategies during 2 years of a randomized controlled trial. Diabetes Care 2013;36:2225-2232. https://doi.org/10.2337/dc12-1846
  46. Bray GA, Heisel WE, Afshin A, et al. The science of obesity management: an endocrine society scientific statement. Endocr Rev 2018;39:79-132. https://doi.org/10.1210/er.2017-00253
  47. Weir MA, Beyea MM, Gomes T, et al. Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med 2011;171:703-704.
  48. Solomon LR, Nixon AC, Ogden L, Nair B. Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease. BMJ Case Rep 2017;2017:bcr2016218623. https://doi.org/10.1136/bcr-2016-218623
  49. Ritchey ME, Harding A, Hunter S, et al. Cardiovascular safety during and after use of phentermine and topiramate. J Clin Endocrinol Metab 2019;104:513-522. https://doi.org/10.1210/jc.2018-01010
  50. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95:297-308. https://doi.org/10.3945/ajcn.111.024927
  51. U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs [Internet]. FDA. [cited 2022 Oct 10]; Available from: https://www.accessdata.fda.gov/scripts/cder/daf/
  52. Kim BY, Kang SM, Kang JH, et al. 2020 Korean Society for the Study of Obesity Guidelines for the Management of Obesity in Korea. J Obes Metab Syndr 2021;30:81-92. https://doi.org/10.7570/jomes21022
  53. Tran S, Retnakaran R, Zinman B, Kramer CK. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2018;20 Suppl 1:68-76. https://doi.org/10.1111/dom.13137
  54. Mann JFE, Fonseca VA, Poulter NR, et al. Safety of liraglutide in type 2 diabetes and chronic kidney disease. Clin J Am Soc Nephrol 2020;15:465-473. https://doi.org/10.2215/CJN.11881019
  55. Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018;6:605-617. https://doi.org/10.1016/S2213-8587(18)30104-9
  56. Mann JFE, Orsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017;377:839-848. https://doi.org/10.1056/NEJMoa1616011
  57. Chang AR, Chen Y, Still C, et al. Bariatric surgery is associated with improvement in kidney outcomes. Kidney Int 2016;90:164-171. https://doi.org/10.1016/j.kint.2016.02.039
  58. Imam TH, Fischer H, Jing B, et al. Estimated GFR before and after bariatric surgery in CKD. Am J Kidney Dis 2017;69:380-388. https://doi.org/10.1053/j.ajkd.2016.09.020
  59. Shulman A, Peltonen M, Sjostrom CD, et al. Incidence of end-stage renal disease following bariatric surgery in the Swedish Obese Subjects Study. Int J Obes (Lond) 2018;42:964-973. https://doi.org/10.1038/s41366-018-0045-x
  60. Chintam K, Chang AR. Strategies to treat obesity in patients with CKD. Am J Kidney Dis 2021;77:427-439. https://doi.org/10.1053/j.ajkd.2020.08.016
  61. Cohen JB, Tewksbury CM, Torres Landa S, Williams NN, Dumon KR. National postoperative bariatric surgery outcomes in patients with chronic kidney disease and end-stage kidney disease. Obes Surg 2019;29:975-982. https://doi.org/10.1007/s11695-018-3604-2
  62. Friedman AN, Kaplan LM, le Roux CW, Schauer PR. Management of obesity in adults with CKD. J Am Soc Nephrol 2021;32:777-790. https://doi.org/10.1681/ASN.2020101472